AAAAAA

   
Results: 1-25 | 26-50 | 51-75 | 76-100 >>
Results: 1-25/100
INDUCTION OF MUC1 SPECIFIC CTL USING 2 NEWLY IDENTIFIED PEPTIDES - IMPLICATIONS FOR BROADLY APPLICABLE CANCER VACCINES
Authors: BROSSART P STUHLER G HEINRICH KS STEFANOVIC S RAMMENSEE HG KANZ L BRUGGER W
Citation: P. Brossart et al., INDUCTION OF MUC1 SPECIFIC CTL USING 2 NEWLY IDENTIFIED PEPTIDES - IMPLICATIONS FOR BROADLY APPLICABLE CANCER VACCINES, Journal of leukocyte biology, 1998, pp. 28-28
MULTICENTER RANDOMIZED PHASE-III STUDY EVALUATING THE ROLE OF HIGH-DOSE CHEMOTHERAPY AND PERIPHERAL-BLOOD PROGENITOR-CELL SUPPORT IN PATIENTS WITH LIMITED-STAGE SMALL-CELL LUNG-CANCER
Authors: BRUGGER W DIERKESMANN R TOOMES H ENGELHARDT R HASSE J PRESSLER K KOLLMANNSBERGER C SCHUMACHER M FROMMHOLD H BAMBERG M KANZ L
Citation: W. Brugger et al., MULTICENTER RANDOMIZED PHASE-III STUDY EVALUATING THE ROLE OF HIGH-DOSE CHEMOTHERAPY AND PERIPHERAL-BLOOD PROGENITOR-CELL SUPPORT IN PATIENTS WITH LIMITED-STAGE SMALL-CELL LUNG-CANCER, Onkologie, 21, 1998, pp. 12-14
CHARACTERIZATION OF AC133-BLOOD AND BONE-MARROW( CELLS FROM HUMAN CORD)
Authors: BUHRING HJ SEIFFERT M GEISELHARDT A THIEL A SCHEFFOLD A BRUGGER W KANZ L
Citation: Hj. Buhring et al., CHARACTERIZATION OF AC133-BLOOD AND BONE-MARROW( CELLS FROM HUMAN CORD), Experimental hematology, 26(8), 1998, pp. 194-194
TRANSPLANTATION OF UNSELECTED OR CD34(-BLOOD PROGENITOR CELLS FROM HLA-MATCHED OR ONE ANTIGEN-MISMATCHED SIBLING DONORS() SELECTED ALLOGENEIC PERIPHERAL)
Authors: BRUGGER W SCHEDING S BRANDES A MANZ M WIESMANN A WEISS B FAUL C EINSELE H KANZ L
Citation: W. Brugger et al., TRANSPLANTATION OF UNSELECTED OR CD34(-BLOOD PROGENITOR CELLS FROM HLA-MATCHED OR ONE ANTIGEN-MISMATCHED SIBLING DONORS() SELECTED ALLOGENEIC PERIPHERAL), Bone marrow transplantation, 21, 1998, pp. 13-13
PILOT-STUDY OF DOUBLE HIGH-DOSE CHEMOTHERAPY WITH PBPC TRANSPLANTATION IN PATIENTS WITH STAGE-III AND STAGE-IV BREAST-CANCER
Authors: MANZ M BRUMMENDORF TH SCHEDING S BRUGGER W KANZ L
Citation: M. Manz et al., PILOT-STUDY OF DOUBLE HIGH-DOSE CHEMOTHERAPY WITH PBPC TRANSPLANTATION IN PATIENTS WITH STAGE-III AND STAGE-IV BREAST-CANCER, Bone marrow transplantation, 21, 1998, pp. 222-222
CMV INFECTION FOLLOWING TRANSPLANTATION OF ALLOGENEIC PERIPHERAL-BLOOD PROGENITOR CELLS FROM RELATED DONORS
Authors: HEBART H BRUGGER W KLINGEBIEL T SINZGER C JAHN G MULLER CA KANZ L EINSELE H
Citation: H. Hebart et al., CMV INFECTION FOLLOWING TRANSPLANTATION OF ALLOGENEIC PERIPHERAL-BLOOD PROGENITOR CELLS FROM RELATED DONORS, Bone marrow transplantation, 21, 1998, pp. 484-484
MULTIMODALITY TREATMENT INCLUDING EARLY HIGH-DOSE CHEMOTHERAPY WITH PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION IN LIMITED-DISEASE SMALL-CELL LUNG-CANCER
Authors: BRUGGER W FETSCHER S HASSE J FROMMHOLD H PRESSLER K MERTELSMANN R ENGELHARDT R KANZ L
Citation: W. Brugger et al., MULTIMODALITY TREATMENT INCLUDING EARLY HIGH-DOSE CHEMOTHERAPY WITH PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION IN LIMITED-DISEASE SMALL-CELL LUNG-CANCER, Seminars in oncology, 25(1), 1998, pp. 42-48
EX-VIVO EXPANSION OF HEMATOPOIETIC PROGENITOR CELLS FOR CLINICAL USE
Authors: SCHEDING S KRATZALBERS K MEISTER B BRUGGER W KANZ L
Citation: S. Scheding et al., EX-VIVO EXPANSION OF HEMATOPOIETIC PROGENITOR CELLS FOR CLINICAL USE, Seminars in hematology, 35(3), 1998, pp. 232-240
HER-2 NEU-DERIVED PEPTIDES ARE TUMOR-ASSOCIATED ANTIGENS EXPRESSED BYHUMAN RENAL-CELL AND COLON-CARCINOMA LINES AND ARE RECOGNIZED BY IN-VITRO INDUCED SPECIFIC CYTOTOXIC T-LYMPHOCYTES/
Authors: BROSSART P STUHLER G FLAD T STEVANOVIC S RAMMENSEE HG KANZ L BRUGGER W
Citation: P. Brossart et al., HER-2 NEU-DERIVED PEPTIDES ARE TUMOR-ASSOCIATED ANTIGENS EXPRESSED BYHUMAN RENAL-CELL AND COLON-CARCINOMA LINES AND ARE RECOGNIZED BY IN-VITRO INDUCED SPECIFIC CYTOTOXIC T-LYMPHOCYTES/, Cancer research, 58(4), 1998, pp. 732-736
TRANSPLANTATION OF CD34(-BLOOD PROGENITOR CELLS FROM HLA-MATCHED OR ONE ANTIGEN-MISMATCHED SIBLING DONORS() POSITIVELY SELECTED OR UNSELECTED ALLOGENEIC PERIPHERAL)
Authors: BRUGGER W SCHEDING S FAUL C HEBART H EINSELE H KANZ L
Citation: W. Brugger et al., TRANSPLANTATION OF CD34(-BLOOD PROGENITOR CELLS FROM HLA-MATCHED OR ONE ANTIGEN-MISMATCHED SIBLING DONORS() POSITIVELY SELECTED OR UNSELECTED ALLOGENEIC PERIPHERAL), British Journal of Haematology, 102(1), 1998, pp. 64-64
GENERATION OF DENDRITIC CELLS FROM ADHERENT PERIPHERAL-BLOOD MONONUCLEAR-CELLS BY CD40 LIGATION IN THE ABSENCE OF GM-CSF
Authors: BROSSART P GRUNEBACH F STUHLER G REICHARDT V MOHLE R KANZ L BRUGGER W
Citation: P. Brossart et al., GENERATION OF DENDRITIC CELLS FROM ADHERENT PERIPHERAL-BLOOD MONONUCLEAR-CELLS BY CD40 LIGATION IN THE ABSENCE OF GM-CSF, British Journal of Haematology, 102(1), 1998, pp. 83-83
PCR-DIRECTED PREEMPTIVE THERAPY PREVENTS CMV-ASSOCIATED MORTALITY DURING THE FIRST 100 DAYS AFTER TRANSPLANT
Authors: HEBART H BRUGGER W KLINGEBIEL T LOFFLER J JAHN G SINZGER C MULLER CA KANZ L EISELE H
Citation: H. Hebart et al., PCR-DIRECTED PREEMPTIVE THERAPY PREVENTS CMV-ASSOCIATED MORTALITY DURING THE FIRST 100 DAYS AFTER TRANSPLANT, British Journal of Haematology, 102(1), 1998, pp. 97-97
PHENOTYPIC CHARACTERIZATION OF AC133-SELECTED BONE-MARROW CELLS
Authors: BUHRING HJ FAUL C KANZ L BRUGGER W
Citation: Hj. Buhring et al., PHENOTYPIC CHARACTERIZATION OF AC133-SELECTED BONE-MARROW CELLS, British Journal of Haematology, 102(1), 1998, pp. 159-159
LOW RESPONSE RATE TO A CONTINUOUS SCHEDULE OF AMIFOSTINE FOR LOW-RISKMYELODYSPLASTIC PATIENTS
Authors: BOWEN DT GELLY K HEPBURN M KANZ L BRUGGER W DENZLINGER C CULLIGAN D
Citation: Dt. Bowen et al., LOW RESPONSE RATE TO A CONTINUOUS SCHEDULE OF AMIFOSTINE FOR LOW-RISKMYELODYSPLASTIC PATIENTS, British Journal of Haematology, 102(1), 1998, pp. 344-344
2',5'-OLIGOADENYLATE-ANTISENSE CHIMERAS CAUSE RNASE-L TO SELECTIVELY DEGRADE BCR ABL MESSENGER-RNA IN CHRONIC MYELOGENOUS LEUKEMIA-CELLS/
Authors: MARAN A WALLER CF PARANJAPE JM LI GY XIAO W ZHANG K KALAYCIO ME MAITRA RK LICHTIN AE BRUGGER W TORRENCE PF SILVERMAN RH
Citation: A. Maran et al., 2',5'-OLIGOADENYLATE-ANTISENSE CHIMERAS CAUSE RNASE-L TO SELECTIVELY DEGRADE BCR ABL MESSENGER-RNA IN CHRONIC MYELOGENOUS LEUKEMIA-CELLS/, Blood, 92(11), 1998, pp. 4336-4343
THE CHEMOKINE RECEPTOR CXCR-4 IS EXPRESSED ON CD34(-CELLS AND MEDIATES TRANSENDOTHELIAL MIGRATION INDUCED BY STROMAL CELL-DERIVED FACTOR-I() HEMATOPOIETIC PROGENITORS AND LEUKEMIC)
Authors: MOHLE R BAUTZ F RAFII S MOORE MAS BRUGGER W KANZ L
Citation: R. Mohle et al., THE CHEMOKINE RECEPTOR CXCR-4 IS EXPRESSED ON CD34(-CELLS AND MEDIATES TRANSENDOTHELIAL MIGRATION INDUCED BY STROMAL CELL-DERIVED FACTOR-I() HEMATOPOIETIC PROGENITORS AND LEUKEMIC), Blood, 91(12), 1998, pp. 4523-4530
PROCEEDINGS OF THE SYMPOSIUM AND WORKSHOP HEMATOPOIETIC STEM-CELLS - INTRODUCTION
Authors: BOCK TA BRUGGER W KANZ L
Citation: Ta. Bock et al., PROCEEDINGS OF THE SYMPOSIUM AND WORKSHOP HEMATOPOIETIC STEM-CELLS - INTRODUCTION, Stem cells, 15, 1997, pp. 1-1
PURGING OF PERIPHERAL-BLOOD PROGENITOR-CELL AUTOGRAFTS AND TREATMENT OF MINIMAL RESIDUAL DISEASE
Authors: BRUGGER W SCHEDING S BOCK T ZIEGLER B KANZ L
Citation: W. Brugger et al., PURGING OF PERIPHERAL-BLOOD PROGENITOR-CELL AUTOGRAFTS AND TREATMENT OF MINIMAL RESIDUAL DISEASE, Stem cells, 15, 1997, pp. 159-165
EVALUATION OF RESIDUAL OR RECURRENT MALIGNANT-LYMPHOMA BY FDG-PET
Authors: SOKLER M DOHMEN BM BOKEMEYER C BRUGGER W KOPP A BARES R KANZ L
Citation: M. Sokler et al., EVALUATION OF RESIDUAL OR RECURRENT MALIGNANT-LYMPHOMA BY FDG-PET, European journal of cancer, 33, 1997, pp. 1189-1189
HELPER T-CELL-DEPENDENT INDUCTION OF HER-2 NEU SPECIFIC CYTOTOXIC T-LYMPHOCYTES BY TUMOR-CELLS, FUSED TO ALLOGENEIC DC/
Authors: STUHLER G BROSSART P BRUGGER W KANZ L
Citation: G. Stuhler et al., HELPER T-CELL-DEPENDENT INDUCTION OF HER-2 NEU SPECIFIC CYTOTOXIC T-LYMPHOCYTES BY TUMOR-CELLS, FUSED TO ALLOGENEIC DC/, Cancer gene therapy, 4(5), 1997, pp. 318-318
DOSE-INTENSE THERAPY WITH ETOPOSIDE, IFOSFAMIDE, CISPLATIN, AND EPIRUBICIN (VIP-E) IN 100 CONSECUTIVE PATIENTS WITH, LIMITED-DISEASE AND EXTENSIVE-DISEASE SMALL-CELL LUNG-CANCER
Authors: FETSCHER S BRUGGER W ENGELHARDT R KANZ L HASSE J FROMMHOLD H WENGER M LANGE W MERTELSMANN R
Citation: S. Fetscher et al., DOSE-INTENSE THERAPY WITH ETOPOSIDE, IFOSFAMIDE, CISPLATIN, AND EPIRUBICIN (VIP-E) IN 100 CONSECUTIVE PATIENTS WITH, LIMITED-DISEASE AND EXTENSIVE-DISEASE SMALL-CELL LUNG-CANCER, Annals of oncology, 8(1), 1997, pp. 49-56
DOSE-INTENSE THERAPY WITH ETOPOSIDE, IFOSFAMIDE, CISPLATIN, AND EPIRUBICIN (VIP-E) IN 107 CONSECUTIVE PATIENTS WITH, LIMITED-STAGE AND EXTENSIVE-STAGE NON-SMALL-CELL LUNG-CANCER
Authors: FETSCHER S BRUGGER W ENGELHARDT R KANZ L HASSE J FROMMHOLD H WENGER M LANGE W MERTELSMANN R
Citation: S. Fetscher et al., DOSE-INTENSE THERAPY WITH ETOPOSIDE, IFOSFAMIDE, CISPLATIN, AND EPIRUBICIN (VIP-E) IN 107 CONSECUTIVE PATIENTS WITH, LIMITED-STAGE AND EXTENSIVE-STAGE NON-SMALL-CELL LUNG-CANCER, Annals of oncology, 8(1), 1997, pp. 57-64
A NEW LOOK AT THE ROLE OF P53 IN LEUKEMIA-CELL SENSITIVITY TO CHEMOTHERAPY
Authors: TREPEL M SCHEDING S GROSCURTH P HORNY HP MALIPIERO U BRUGGER W DICHGANS J WELLER M
Citation: M. Trepel et al., A NEW LOOK AT THE ROLE OF P53 IN LEUKEMIA-CELL SENSITIVITY TO CHEMOTHERAPY, Leukemia, 11(11), 1997, pp. 1842-1849
TRANSPLANTATION OF ALLOGENEIC PERIPHERAL-BLOOD CD34(-MATCHED OR 1 ANTIGEN-MISMATCHED SIBLING DONORS() CELLS FROM HLA)
Authors: BRUGGER W SCHEDING S MANZ M BRUMMENDORF T FAUL C BRANDES A WIESMANN A WEISS B EINSELE H KANZ L
Citation: W. Brugger et al., TRANSPLANTATION OF ALLOGENEIC PERIPHERAL-BLOOD CD34(-MATCHED OR 1 ANTIGEN-MISMATCHED SIBLING DONORS() CELLS FROM HLA), Experimental hematology, 25(8), 1997, pp. 182-182
FLT-3 LIGAND PROMOTES THE EX-VIVO GENERATION OF GRANULOPOIETIC POST-PROGENITOR CELLS FOR CLINICAL USE AFTER PERIPHERAL-BLOOD PROGENITOR-CELL (PBPC) TRANSPLANTATION
Authors: SCHEDING S MEISTER B BAUM C MCKEARN J BUHRING HJ ZIEGLER B BOCK T KANZ L BRUGGER W
Citation: S. Scheding et al., FLT-3 LIGAND PROMOTES THE EX-VIVO GENERATION OF GRANULOPOIETIC POST-PROGENITOR CELLS FOR CLINICAL USE AFTER PERIPHERAL-BLOOD PROGENITOR-CELL (PBPC) TRANSPLANTATION, Experimental hematology, 25(8), 1997, pp. 267-267
Risultati: 1-25 | 26-50 | 51-75 | 76-100 >>